Advertisement

Immunotherapy of CMV Infections

  • David P. Paar
  • Richard B. Pollard
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 394)

Abstract

Although cytomegalovirus (CMV) infection is common, the majority of infections cause little or no symptoms. Serious disease occurs virtually exclusively in fetuses or neonates and immunosuppressed individuals including those on corticosteroids, transplant recipients, and those with the acquired immunodeficiency syndrome (AIDS). Retinitis, gastrointestinal disease, and interstitial pneumonitis are among the more common manifestations of CMV disease, but infections at other sites also occur.

Keywords

Adoptive Transfer Graft Versus Host Disease Fred Hutchinson Cancer Research Antiidiotype Antibody Graft Versus Host 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Shepp DH, Dandliker PS, Miranda P, et al. “Activity of 9-[2-Hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine in the Treatment of Cytomegalovirus Pneumonia.” Annals of Internal Medicine. 1985; 103: 368–373.PubMedCrossRefGoogle Scholar
  2. 2.
    Grundy, J. “Virologie and Pathogenetic Aspects of Cytomegalovirus Infections.” Reviw of Infectious Diseases. 1990; 12 (Suppl. 7): S711–9.CrossRefGoogle Scholar
  3. 3.
    Meyers JD, Floumoy N, Thomas ED. “Risk Factors for Cytomegalovirus Infection after Human Marrow Transplantation.” Journal of Infectious Diseases. 1986; 153: 478–88.PubMedCrossRefGoogle Scholar
  4. 4.
    Bratanow NC, Ash RC, Turner PA, et al. “Successful Treatment of Serious Cytomegalovirus Disease with 9 (1,3-dihydroxy-2-propoxymethyl) Guanine in Bone Marrow Transplant Patients. Blood. 1986;68 Suppl. 1: 280aGoogle Scholar
  5. 5.
    Emanual D, Cunningham I, Jules-Eleysee K, et al. “Cytomegalovirus Pneumonia after Bone Marrow Transplantation Successfully Treated with the Combination of Ganciclovir and High-Dose Intravenous Immune Globulin.” Annals of Internal Medicine. 1988; 109: 777–82.CrossRefGoogle Scholar
  6. 6.
    Reed EC, Bowden RA, Dandliker PS, et al. “Treatment of Cytomegaaovins Pneumonia with Ganciclovir and Intravenous Cytomegalovirus Immunoglobulin in Patients with Bone Marrow Transplants.” Annals of Internal Medicine. 1988; 109; 783–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Schmidt GM, Kovacs A, Zaia JA, et al. “Ganciclovir/Immunoglobulin Combination Therapy for the Treatment of Human Cytomegalovirus-Associated Interstitial Pneumonia in Bone Marrow Allograft Recipients.” Transplantation. 1988; 46: 905–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Crawford SW, Bowden RA, Hackman RC, et al. “Rapid Detection of Cytomegalovirus Pulmonary Infection by Bronchoalveolar Lavage and Centrifugation Culture.” Annals of Internal Medicine. 1988; 108: 180–5.PubMedCrossRefGoogle Scholar
  9. 9.
    Emanual DJ. “Uses of Immunotherapy for Control of Human Cytomegalovirus-Associated Dicrases.” Transplantation Proceedings. 1991;23,Suppl 3: 144–6.Google Scholar
  10. 10.
    Chatenoud L. “The Immune Response Against Therapeutic Monoclonal Antibodies.” Immunology Today. 1986; 7: 367–8.CrossRefGoogle Scholar
  11. 11.
    Khazaeli MB, Mansoor NS, Wheeler RH, et al. “Phase I Trial of Multiple Large Doses of Murine Monoclonal Antibody CO17–1A. II. Pharmacokinetics and Immune Response.” Journal of the National Cancer Institute. 1988; 80: 937–42.PubMedCrossRefGoogle Scholar
  12. 12.
    Aulitzky WE, Schulz TF, Tilg H, et al. “Human Monoclonal Antibodies Neutralizing Cytomegalovirus (CMV) for Prophylaxis of CMV Disease: Report of a Phase I Trial in Bone Marrow Transplant Recipients.” Journal of Infectious Diseases. 1991;163:1344–7_Google Scholar
  13. 13.
    Azuma J, Kurimoto T, Tsuji S, et al. “Phase I Study on Human Monoclonal Antibody Against Cytomegalovirus: Pharmacokinetics and Immunogenicit.” Journal of Immunotherapy. 1991; 10: 278–85.PubMedCrossRefGoogle Scholar
  14. 14.
    Hagenbeek A, Brummelhuis HGJ, Donkers A, et al. “Rapid Clearance of Cytomegalovirus-Specific IgG After Repeated Intravenous Infusions of Human Immunoglobulin into Allogeneic Bone Marrow Transplant Recipients.” Journal of Infectious Diseases. 1987; 155: 897–902.PubMedCrossRefGoogle Scholar
  15. 15.
    Petersen E, Kaplan C, Fish D, et al. “Human Monoclonal Antibody to Cytomegalvirus (TI-23): Pharmacokinetics and Toxicity Study in HIV Seropositive Patients.” Sixth International Conference on AIDS. June 20, 1990.Google Scholar
  16. 16.
    Pollard RB, Nokta MA, Pappas P, et al. “A Phase I/IIA Study of a Human Monoclonal Anti-Cytomegalovirus Antibody in Patients with AIDS.” Antiviral Research, 1992;16, Suppl 1: 111.Google Scholar
  17. 17.
    Tolpin M, Pollard R, Tierney M, et al. “Combination Therapy of Cytomegalovirus (CMV) Retinitis with a Human Monocloncal Anti-CMV Antibody (SDZ MSL 109) and Either Ganciclovir (DHPG) or Foscarnet (PFA).” IXth International Conference on AIDS. June 6–11, 1993.Google Scholar
  18. 18.
    Quitman GV, Kimiani N, Rood AH, et al. “Cytotoxic T Cells in Cytomegalovirus Infection.” New England Journal of Medicine. 1982; 307: 7–13.CrossRefGoogle Scholar
  19. 19.
    Greenberg PD, Renccer P, Goodrich JM, et al. “Development of a Treatment Regimen for Human Cytomegalovirus (CMV) Infection in Bone Marrow Transplantation Receipients by Adoptive Transfer of Donor-Derived CMV-Specific T Cell Clones Expanded In Vitro Annals New York Academy of Sciences. 1991; 636: 184–95.CrossRefGoogle Scholar
  20. 20.
    Riddell SR, Watanabe KS, Goodrich JM, et al. “Restoration of Viral Immunity in Immunodeficient Humans by the Adoptive Transfer of T Cell Clones.” Science. 1992; 257: 238–41.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • David P. Paar
  • Richard B. Pollard

There are no affiliations available

Personalised recommendations